does tirzepatide cause gallstones and Gallstones: Safety Guide Gastrointestinal safety of semaglutide and

The doses discussed online are based on clinical trials only

Berg JK, Kim EH, Li B, Joelsson B, Youssef NN

Initiation of GLP-1 receptor agonists in post-bariatric patients follows similar protocols to other populations, with gradual dose escalation to minimise gastrointestinal side effects

Tirzepatide, a newer dual GLP-1/GIP receptor agonist, demonstrated even larger reductions in some studies, with systolic decreases reaching 68 mmHg in overweight patients

Hypersensitivity reactions , though rare, can occur and may include rash, pruritus, or more severe anaphylactic reactions

More serious but less common or even rare side effects include a risk for thyroid cancer, inflammation of the pancreas, gallstones, and low blood sugar (hypoglycemia)